12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-809: Phase IIa started

Vertex began a 3-part, double-blind, international Phase IIa trial to evaluate a combination of CFTR regulators VX-770 and VX-809 in up to 160 patients with 2 copies of the delta F508 CFTR mutation. In the first part of the trial, 2...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >